Trial · NCT07889297
Pulsed Field Ablation for the Treatment of Malignant Lung Tumors
NCT07889297, Not applicable, Not yet recruiting, Shanghai Chest Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pulsed Field Ablation for the Treatment of Malignant Lung Tumors. Trials, record NCT07889297. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07889297
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pulsed Field Ablation for the Treatment of Malignant Lung Tumors
- NCT number
- NCT07889297
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 15 participants, estimated
- Lead sponsor
- Shanghai Chest Hospital
- Conditions
- Non-Small Cell Lung Cancer, Pulmonary Metastases
- Interventions
- Pulsed Field Ablation System and Single-Use Pulsed Field Ablation Catheter
- First posted
- 2026-10-22
- Last updated
- 2026-10-22
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete Ablation Rate at 6 Months (Lesion-Level) | 6 months after completion of the ablation procedure | The percentage of evaluable treated lung lesions that maintain complete ablation at 6 months after completion of the ablation procedure. Complete ablation is assessed by computed tomography (CT) and is defined as a target lesion that has decreased or remained unchanged in size and shows no contrast enhancement. Nonenhancing cavities, solid nodules, atelectasis, or fibrosis may be considered findings consistent with complete ablation according to the protocol-defined criteria. The rate is calculated as the number of evaluable lesions meeting the complete ablation criteria divided by the total number of evaluable ablated lesions, multiplied by 100%. |
| Secondary | Technical Success Rate | Immediately after each ablation procedure | The percentage of ablation procedures in which the investigational devices are successfully advanced to the target lesion, the planned ablation procedure is completed, and the devices are successfully withdrawn. The rate is calculated as the number of technically successful procedures divided by the total number of ablation procedures, multiplied by 100%. |
| Secondary | Complete Ablation Rate at 6 Months (Participant-Level) | 6 months after completion of the overall ablation procedure | The percentage of evaluable participants for whom all treated lung lesions maintain complete ablation at 6 months after completion of the overall ablation procedure. Complete ablation is assessed by CT and is defined as a target lesion that has decreased or remained unchanged in size and shows no contrast enhancement. |
| Secondary | Intrapulmonary Progression-Free Survival Rate at 6 Months | 6 months after completion of the overall ablation procedure | The percentage of evaluable participants without intrapulmonary disease progression at 6 months. Absence of intrapulmonary progression is defined as maintenance of complete ablation of the originally treated lesions, no hilar lymph node metastasis, and no new intrapulmonary lesions. |
| Secondary | Overall Survival Rate at 6 Months | 6 months after enrollment | The percentage of enrolled participants who are alive at 6 months after enrollment. |
| Secondary | Change From Baseline in EORTC QLQ-C30 Scores | Baseline, 7 days or before discharge, and 1, 3, and 6 months after completion of the overall ablation procedure | Quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Scores at each post-treatment visit and changes from baseline will be summarized according to the standard scoring procedures for the questionnaire. |
| Other | Incidence of Adverse Events and Serious Adverse Events | From the start of the ablation procedure through 6 months after completion of the overall ablation procedure | The number and percentage of participants experiencing adverse events and serious adverse events during the study. Adverse events will be evaluated using CTCAE version 6.0 when applicable. All adverse events, serious adverse events, device-related adverse events, and procedure-related adverse events will be summarized separately. The severity, outcome, and relationship of each event to the investigational devices and ablation procedure will be assessed and recorded. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07889297
GET https://conductscience.org/api/trials/v1/NCT07889297/registered